Results 51 to 60 of about 2,517,016 (285)

The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens

Journal of Fungi, 2020
Human fungal pathogens are attributable to a significant economic burden and mortality worldwide. Antifungal treatments, although limited in number, play a pivotal role in decreasing mortality and morbidities posed by invasive fungal infections (IFIs ...
Amir Arastehfar, Cornelia Lass-Flörl, Rocio Garcia-Rubio, Farnaz Daneshnia, Macit Ilkit, Teun Boekhout, Toni Gabaldon, David S. Perlin   +7 more
doaj   +1 more source

KAJIAN MOLEKULER RESISTENSI Candida albicans TERHADAP ANTIFUNGI

Jurnal Farmasi Sains dan Komunitas, 2014
: Candida albicans is one of the species Candida which mostly cause infection in human. Antifungal agent azole, polyene, echinocandin, and flucytosine are commonly used for Candida albicans infection treatment.
Damiana Sapta Candrasari
doaj   +1 more source

Antifungal Resistance and New Strategies to Control Fungal Infections

International Journal of Microbiology, 2012
Despite improvement of antifungal therapies over the last 30 years, the phenomenon of antifungal resistance is still of major concern in clinical practice.
Patrick Vandeputte, Selene Ferrari, Alix T. Coste   +2 more
doaj   +1 more source

ABC transporters and azole susceptibility in laboratory strains of the wheat pathogen Mycosphearella graminicola [PDF]

, 2002
Laboratory strains of Mycosphaerella graminicola with decreased susceptibilities to the azole antifungal agent cyproconazole showed a multidrug resistance phenotype by exhibiting cross-resistance to an unrelated chemical, cycloheximide or rhodamine 6G ...
Nistelrooy, J.G.M., Van, Zwiers, L.H., Stergiopoulos, I., Waard, M.A., De, Lute-harm Zwiers, Johannes G. M. Van Nistelrooy, Van Nistelrooy, Maarten A. De Waard, Johannes G. M, Ioannis Stergiopoulos   +9 more
core   +1 more source

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. [PDF]

, 2013
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice.
A. Loyse, Dromer, F, Day, J, Lortholary, O, O. Lortholary, Harrison, TS, F. Dromer, T. S. Harrison, J. Day, Loyse, A   +9 more
core   +1 more source

Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. [PDF]

, 2009
Contains fulltext : 81920.pdf (Publisher’s version ) (Open Access)We reported the emergence of resistance to medical triazoles of Aspergillus fumigatus isolates from patients with invasive aspergillosis.
Melchers, W.J.G., A. J. M. M. Rijs, Veld, R., G. H. J. Kema, Verweij, P.E., Snelders, E., Kema, G.H.J., W. J. G. Melchers, Kema, G.H., E. Snelders, Rijs, A., Rijs, A.J.M.M., Huis In 't Veld, R.A., P. E. Verweij, R. A. G. Huis in 't Veld   +14 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source